Specialty pharmaceutical company primarily focused on the sales, marketing and development of branded pharmaceutical products
Location: United States, Texas, Houston
Total raised: $248M
Investors 1
| Date | Name | Website |
| - | Aisling Ca... | aislingcap... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 20.08.2014 | - | $220M | - |
| 21.07.2011 | - | $28M | - |
Mentions in press and media 3
| Date | Title | Description |
| 17.04.2015 | Pernix Therapeutics Announces Pricing of Private Offering of $130 Million of 4.25% Convertible Senior Notes Due 2021 | Morristown, New Jersey, April 17, 2015 – Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX) (the “Company”) today announced that it has priced a private offering of $130 million aggregate principal amount of the Company’s 4.25% Convertible Se... |
| 20.08.2014 | Pernix Therapeutics Closes on Acquisition of Treximet. Raises $220m Senior Notes. Issues Updated 2014 Guidance. | MORRISTOWN, NJ, August 20, 2014 – Pernix Therapeutics Holdings, Inc. (NASDAQ GM: PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, announced today that it has closed its acquisition of Treximet® (sumatriptan / naproxen s... |
| 21.07.2011 | Pernix Announces Pricing of $28 Million Underwritten Registered Direct Offering of Common Stock | - |